Pancreatitis in the product documents
All three regulators carry a pancreatitis warning for Saxenda®, and post-approval reports include haemorrhagic and necrotising pancreatitis, sometimes fatal. [1][2][3] The EU classes pancreatitis as uncommon, meaning fewer than one person in 100. [2]
| Measure | Saxenda® | Placebo | Source |
|---|---|---|---|
| Acute pancreatitis confirmed by adjudication, adults | 9 of 3,291 (0.3%) | 2 of 1,843 (0.1%) | US 6.1; Canada 7 [1][3] |
| Additional cases after stopping, adults | 4 | — | US 6.1 [1] |
| Pancreatitis, ages 12–17 (not adjudicated) | 1 of 125 (0.8%) | — | US 6.1 [1] |
| Increased lipase reported as a reaction, adults | 5.3% | 2.2% | US Table 2 [1] |
| Lipase at least 3 times the upper normal limit | 2.1% | 1.0% | US 6.1 [1] |
| Pancreatitis | Uncommon | — | EU Table 4 [2] |
Reading the trial cases
An expert committee reviewed suspected cases and confirmed nine on Saxenda® and two on placebo during treatment. [1] Two people who had left the trials early developed pancreatitis 74 and 124 days after their last dose, one case came within two weeks of stopping, and another occurred 106 days after completing treatment. [1] Liraglutide has a half-life of about 13 hours, so the later cases happened long after the medicine would have cleared. [1] The label does not say whether they were related.
In the teenage trial, one person on Saxenda® had pancreatitis, which was not independently adjudicated and led to stopping treatment. [1] In SCALE Diabetes, which enrolled 846 adults with type 2 diabetes, no pancreatitis was reported. [7]
People with a history of pancreatitis were excluded from the Saxenda® trials, so it is unknown whether they face a higher risk. [3]
What pooled analyses and meta-analyses add
A secondary analysis of four SCALE trials with 5,358 people found that liraglutide 3 mg raised average lipase by 31% and amylase by 7%, rises that reversed after stopping. Lipase above the normal limit was seen in 43.5% on liraglutide against 15.1% on placebo, yet these rises had very low predictive value for pancreatitis: under 1%. [4] Of 13 people who developed acute pancreatitis, 12 were on or after liraglutide, and 6 of the 13 had gallstone disease at onset. [4] The authors found no basis for routine enzyme monitoring unless pancreatitis is suspected. [4]
Looking across all GLP-1 medicines, a 2025 meta-analysis of 55 placebo-controlled trials with 106,395 people found they probably have little or no effect on pancreatitis risk, while they did raise the risk of gallstones. [5] A 2026 analysis of EU spontaneous reports found a significant but small pancreatitis signal for semaglutide, liraglutide and tirzepatide, reported more often by healthcare professionals. [6] Reports of this kind cannot establish cause.
Taken together: the Saxenda® trials showed a small excess, gallstones may explain part of it, and the label keeps pancreatitis as a warning regardless. [1][4]
How pancreatitis feels
The label describes persistent or severe belly pain, sometimes spreading to the back, with or without nausea and vomiting. [1] MedlinePlus’s liraglutide page says the pain may begin in the upper left or middle of the stomach. [9] The Canadian monograph adds that the pain can be persistent or intermittent. [3]
MedlinePlus describes acute pancreatitis pain as becoming constant and more severe over days, sometimes worse when lying flat or soon after fatty food, and often spreading to the back or below the left shoulder blade. People often look ill, with fever, nausea, vomiting and sweating, and may have a swollen belly, indigestion or mild yellowing of the skin. [8]
Other causes of pancreatitis
- Gallstones are the most common cause, when a stone blocks the duct that drains the pancreas. [8] Saxenda® itself raises gallstone risk. [1]
- Heavy alcohol use over years. [8]
- Very high triglycerides, some medicines such as oestrogens, corticosteroids, sulfonamides, thiazide diuretics and azathioprine, and certain procedures on the bile ducts. [8]
- Autoimmune disease, abdominal injury, an overactive parathyroid gland, cystic fibrosis and infections such as mumps. [8]
What happens next, according to the sources
If pancreatitis is suspected, the US label tells prescribers to stop Saxenda® and start appropriate management; the Canadian monograph adds confirmatory tests, and the EU summary says liraglutide should not be restarted if acute pancreatitis is confirmed. [1][2][3]
MedlinePlus explains that treatment often needs a hospital stay with pain relief, fluids into a vein and, sometimes, removal of gallstones or drainage. To lower the risk of repeat attacks, it lists avoiding alcohol if it was the likely cause, not smoking, treating high triglycerides and, if your provider agrees, nutrition counselling for a low-fat diet. [8]
Before starting Saxenda®, the Medication Guide asks you to tell your provider if you have or have had problems with your pancreas. [1]
Saxenda® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe belly pain that will not go away, possibly spreading to the back, with or without vomiting | Stop Saxenda® and get medical help straight away | Emergency | Medication Guide [1]; EU leaflet [2] |
| Intense, constant belly pain with fever, a swollen belly or yellowing skin | Emergency care | Emergency | MedlinePlus [8] |
| Pain that comes and goes in the upper belly after meals, especially with nausea | Your prescriber the same day | Today | Canadian monograph [3]; MedlinePlus [8] |
| A raised lipase result without symptoms | Discuss with your prescriber | At your next appointment | Prescribing Information [1]; Steinberg 2017 [4] |
| Past pancreatitis, gallstones, heavy drinking or high triglycerides before starting Saxenda® | Tell your prescriber before you start | At your next appointment | Medication Guide [1]; Canadian leaflet [3] |
